AstraZeneca stock price forecast: failed LATIFY trial and resistance challenges as AZN slips

Traders Union
All News
Financial News
AstraZeneca slides 0.89% to GBX 13,550

Highlights

AstraZeneca's LATIFY Phase III trial combining ceralasertib and Imfinzi in advanced non-small cell lung cancer failed to meet its primary overall survival endpoint.
AstraZeneca secured a global exclusive license deal with Jacobio Pharma for pan-KRAS inhibitor JAB-23E73, involving a $100 million upfront payment and up to $1.915 billion in milestones.
AstraZeneca initiated a Phase 3 trial of ENHERTU with Daiichi Sankyo for adjuvant endometrial cancer treatment and reported recent institutional and insider shareholding changes.

Mixed clinical outcomes and licensing deals shift sentiment drivers

AstraZeneca reported that its LATIFY Phase III trial studying ceralasertib combined with Imfinzi in advanced non-small cell lung cancer did not meet its primary outcome for overall survival. The company also entered into a global exclusive license with Jacobio Pharma for the pan-KRAS inhibitor JAB-23E73, which includes a $100 million upfront payment and the potential for up to $1.915 billion in future milestone payments. Additionally, AstraZeneca began a Phase 3 trial of ENHERTU with Daiichi Sankyo in adjuvant treatment for endometrial cancer and disclosed recent institutional shareholding changes and insider share sales.

Technical resistance as mixed momentum signals warning for buyers

Momentum indicators are mixed: MACD and ADX show ongoing bullish momentum, while RSI (57.69) signals buyers remain in control. However, Stoch RSI is neutral and CCI is overbought, indicating some caution is warranted as the asset approaches elevated levels. BBP D1 shows a strong overbought reading, highlighting buyer dominance in the current session. The Awesome Oscillator is neutral, not providing additional trend confirmation. The nearest dynamic resistance is the Ichimoku Kijun at GBX 14,418.18, with MA-50 acting as the closest support.

Bullish bias underpins limited downside risk in weekly forecast

For the upcoming week, the expected range is normalized to GBX 13,250 – 13,850, which represents a typical volatility band relative to current levels for a large-cap stock. Based on strong bullish signals from RSI, ADX, MACD, and long-term moving averages on the weekly chart, the probability of a price increase is very high (more than 80%), while the chance of a decline is very low. The baseline scenario is for sideways movement within the established corridor. A bullish scenario emerges if AZN breaks above GBX 13,850, signaling further upside, while a drop below GBX 13,250 could open the way for deeper support tests.

Viktoras Karapetjanc, analyst at Traders Union, sees AstraZeneca as fundamentally strong despite recent mixed clinical trial outcomes. He believes positive momentum from new licensing deals and continued institutional interest underpins a bullish outlook. Support remains robust above MA-50, and sentiment and trend indicators point to buyer control. Macro volatility is well-contained within the established range. "Given AstraZeneca’s robust pipeline and bullish technical setup, I anticipate further upside if GBX 13,850 is surpassed next week."

Last time, analysts noted that AstraZeneca PLC remained in a sideways trading range, with the price holding above its 50- and 200-day moving averages but showing near-term weakness below the 20-day average. Momentum signals such as MACD were supportive, while mixed oscillators and resistance at the Ichimoku Kijun suggested soft conviction and a high likelihood of continued consolidation within a narrow, mildly upward-biased band.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.